Brokers Set Expectations for COMPASS Pathways plc's FY2024 Earnings (NASDAQ:CMPS)

COMPASS Pathways plc (NASDAQ:CMPS - Free Report) - Investment analysts at Cantor Fitzgerald lifted their FY2024 EPS estimates for shares of COMPASS Pathways in a report issued on Monday, March 4th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will post earnings of ($2.47) per share for the year, up from their previous estimate of ($2.90). The consensus estimate for COMPASS Pathways' current full-year earnings is ($2.56) per share.

Other equities research analysts have also issued reports about the stock. Deutsche Bank Aktiengesellschaft began coverage on shares of COMPASS Pathways in a research note on Tuesday, December 12th. They issued a "buy" rating and a $16.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $120.00 price target on shares of COMPASS Pathways in a research note on Friday, March 1st. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, COMPASS Pathways currently has an average rating of "Buy" and an average target price of $49.00.

COMPASS Pathways Stock Up 0.4 %

CMPS opened at $10.91 on Thursday. COMPASS Pathways has a 12 month low of $5.01 and a 12 month high of $12.75. The firm's fifty day simple moving average is $10.05 and its 200 day simple moving average is $8.20. The company has a quick ratio of 13.33, a current ratio of 13.33 and a debt-to-equity ratio of 0.14.

Institutional Investors Weigh In On COMPASS Pathways

A number of institutional investors have recently made changes to their positions in CMPS. Quest Partners LLC bought a new stake in shares of COMPASS Pathways during the 4th quarter valued at about $33,000. UBS Group AG boosted its position in shares of COMPASS Pathways by 249.1% during the 4th quarter. UBS Group AG now owns 4,291 shares of the company's stock valued at $34,000 after purchasing an additional 3,062 shares in the last quarter. Quantbot Technologies LP boosted its position in shares of COMPASS Pathways by 156.8% during the 1st quarter. Quantbot Technologies LP now owns 3,338 shares of the company's stock valued at $43,000 after purchasing an additional 2,038 shares in the last quarter. Advisor Group Holdings Inc. boosted its position in shares of COMPASS Pathways by 129.7% during the 4th quarter. Advisor Group Holdings Inc. now owns 5,406 shares of the company's stock valued at $43,000 after purchasing an additional 3,052 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in COMPASS Pathways by 229.6% in the third quarter. Tower Research Capital LLC TRC now owns 7,847 shares of the company's stock worth $58,000 after acquiring an additional 5,466 shares in the last quarter. Institutional investors own 18.13% of the company's stock.

Insider Transactions at COMPASS Pathways

In other news, Director Ekaterina Malievskaia sold 19,853 shares of the company's stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $10.59, for a total transaction of $210,243.27. Following the completion of the sale, the director now owns 4,144,994 shares of the company's stock, valued at approximately $43,895,486.46. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other COMPASS Pathways news, Director George Jay Goldsmith sold 25,750 shares of the company's stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $8.35, for a total value of $215,012.50. Following the completion of the transaction, the director now owns 4,172,404 shares of the company's stock, valued at approximately $34,839,573.40. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Ekaterina Malievskaia sold 19,853 shares of the company's stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $10.59, for a total value of $210,243.27. Following the completion of the transaction, the director now directly owns 4,144,994 shares of the company's stock, valued at approximately $43,895,486.46. The disclosure for this sale can be found here. In the last 90 days, insiders sold 98,290 shares of company stock valued at $913,996. Company insiders own 23.99% of the company's stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.